Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?

  • Ravin Ratan
  • Shreyaskumar R. Patel
Sarcoma (SH Okuno, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Sarcoma

Opinion Statement

Trabectedin and eribulin are two agents that have been recently approved for the treatment of specific soft tissue sarcoma subtypes. They have proved to be a much-needed line of additional treatment for patients with these rare tumors, but their activity remains admittedly modest in most cases. Further exploitation of these novel agents is likely to require a more granular understanding of the salient mechanisms of action. For example, if as some studies suggest, eribulin derives its benefit from restructuring of tumor vasculature to improve efficacy of subsequent lines of therapy, then patients may benefit from its use earlier in the treatment pathway. The sequencing of trabectedin with other agents is also worth examining. In a disease like myxoid liposarcoma, consideration should be given to using trabectedin before other salvage regimens like gemcitabine and docetaxel, given its tolerability and excellent efficacy against this sarcoma subtype. Also, to be further investigated is the use of trabectedin in sarcoma subtypes which were excluded from the phase III study, but in which activity has been documented in earlier trials and subsequent reports. Combinations of trabectedin with other agents, particularly doxorubicin, have been explored, but the data to date do not support the routine use of these regimens.


Soft tissue sarcoma Trabectedin Eribulin Liposarcoma Leiomyosarcoma 


Compliance with Ethical Standards

Conflict of Interest

Ravin Ratan declares that he has no conflict of interest.

Shreyaskumar R. Patel has received compensation from Janssen, Eisai, EMD-Serono, CytRx, Bayer, and Eli Lilly for service as a consultant, and financial support through grants from Janssen, Eisai, and Morphotek.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016;122(19):2952–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients—preliminary evidence of activity. J Clin Oncol. 2001;19(5):1248–55.CrossRefPubMedGoogle Scholar
  3. 3.
    Taamma A, Misset JL, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001;19(5):1256–65.CrossRefPubMedGoogle Scholar
  4. 4.
    Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, et al. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. Ann Oncol. 2016;27(3):487–93.CrossRefPubMedGoogle Scholar
  5. 5.
    • D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010;9(8):2157–63. A review of the science underlying the complex mechanisms of action ascribed to trabectedinCrossRefPubMedGoogle Scholar
  6. 6.
    Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8(2):449–57.CrossRefPubMedGoogle Scholar
  7. 7.
    Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, et al. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis(R), ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2012;59(5):865–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001;7(2):231–42.PubMedGoogle Scholar
  9. 9.
    Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer. 2003;39(13):1842–51.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188–96. The phase III randomized trial that demonstrated the superiority of trabectedin over dacarbazine with respect to progression-free survival but not overall survival (its primary endpoint). This lead to FDA approval of trabectedin.CrossRefPubMedGoogle Scholar
  11. 11.
    Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European organisation for the research and treatment of cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23(3):576–84.CrossRefPubMedGoogle Scholar
  12. 12.
    Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23(24):5484–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Schwartz GK. Trabectedin and the L-Sarcomas: A Decade-Long Odyssey. J Clin Oncol. 2015.Google Scholar
  14. 14.
    Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. European journal of cancer (Oxford, England : 1990). 2012;48(16):3036–44.CrossRefGoogle Scholar
  15. 15.
    Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014;50(6):1137–47.CrossRefPubMedGoogle Scholar
  16. 16.
    Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, et al. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anti-Cancer Drugs. 2015;26(6):678–81.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001;7(10):3251–7.Google Scholar
  18. 18.
    Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi A, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol. 2003;52(2):131–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Blay JY, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res. 2008;14(20):6656–62.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer. 2009;45(7):1153–61.CrossRefPubMedGoogle Scholar
  21. 21.
    Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20(12):2824–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a gynecologic oncology group study. Gynecol Oncol. 1996;62(2):226–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015;16(4):457–64.CrossRefPubMedGoogle Scholar
  24. 24.
    Martin-Broto J, Pousa AL, de Las PR, Garcia Del Muro X, Gutierrez A, Martinez-Trufero J, et al. Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish Group for Research on Sarcoma Study. J Clin Oncol. 2016;34(19):2294–302.CrossRefPubMedGoogle Scholar
  25. 25.
    Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105(10):1334–42.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015;21(11):2445–52.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23.CrossRefPubMedGoogle Scholar
  28. 28.
    Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12(11):1045–52.CrossRefPubMedGoogle Scholar
  29. 29.
    •• Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016. This phase III randomized study demonstrated the overall survival benefit of eribulin over dacarbazine with respect to its primary endpoint of overall survival.Google Scholar
  30. 30.
    Chawla S, Schoffski P, Grignani G, Blay JY, Maki R, d'Adamo D, et al. Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS). J Clin Oncol. 2016;34(suppl):Abstr 11037.Google Scholar
  31. 31.
    Young RJ. Woll PJ. Lancet: Eribulin in soft-tissue sarcoma; 2016.Google Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Sarcoma Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations